White House Introduces New Drug Price Agreements
In an event at the White House, President Trump revealed arrangements with nine pharmaceutical firms aimed at aligning the cost of drugs in the U.S. with those in other affluent countries.
The administration successfully secured commitments from nine additional drug manufacturers to adhere to pricing that reflects the rates seen in wealthier nations. Currently, fourteen companies have entered into what is now termed as most-favored-nation pricing agreements.
Participating Companies
The companies participating in this initiative include: Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi.
These firms have agreed to not charge the U.S. government more for newly introduced drugs than the prices offered to other prosperous nations, facilitating state Medicaid programs to obtain reduced prices, a move which the White House predicts will generate ‘billions in savings’.
Economic and Consumer Impact
In another significant move, these companies will channel at least $150 billion into U.S.-based pharmaceutical production. The administration is keen to bolster domestic drug manufacturing activities.
Moreover, some popular drugs will also be made available at reduced rates directly to consumers via a government-hosted portal. This initiative will be dubbed TrumpRx and expects to roll out in early 2026, guiding users towards the pharmaceutical companies' direct-selling websites.
Examples from the announcement include Merck's plan to lower the price of Januvia, a treatment for Type 2 diabetes, from $330 to $100 if purchased through TrumpRx. Similarly, Amgen will cut the cost of Repatha, used to control cholesterol levels, from $573 to $239.
The participating companies will also receive a three-year exemption from potential administrative tariffs, in exchange for their price reductions.
Clarifying Consumer Savings
While Medicaid and its users currently benefit from some of the lowest medication prices, the actual savings for consumers through these new agreements remain uncertain. Those with health insurance might still find their copayments to be more cost-effective than direct cash transactions.
Future Prospects
During the announcement, President Trump emphasized an interest in persuading health insurers to also reduce their prices.
"I plan to convene a meeting with insurance companies," the President remarked. "I aim to see if we can bring their prices down, to put it quite plainly."



Leave a Reply